 |
16 Products |  |
56 Diseases | | 16 Products |
|
40 Trials |  |
926 News |  |
| «12345678910111213» |
- ||| Gammanorm (human immune globulin subcutaneous) / Octapharma
New trial: The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency (clinicaltrials.gov) - Dec 12, 2017
P=N/A, N=200, Recruiting, Sponsor: Octapharma
- | Octagam (intravenous normal human immunoglobulin) / Octapharma
New P4 trial: A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) (clinicaltrials.gov) - Nov 21, 2017
P4, N=21, Not yet recruiting, Sponsor: IMMUNOe Research Centers
- ||| Wilate (human factor VIII/von Willebrand factor) / Octapharma, Nuwiq (simoctocog alfa) / Octapharma
New trial: PREVAIL: Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (clinicaltrials.gov) - Nov 17, 2017
P=N/A, N=80, Not yet recruiting, Sponsor: Octapharma
- | Octagam (intravenous normal human immunoglobulin) / Octapharma
New trial, Adverse events, IO biomarker: The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations (clinicaltrials.gov) - Nov 13, 2017
P=N/A, N=15, Completed, Sponsor: IMMUNOe Research Centers
- | Octagam (intravenous normal human immunoglobulin) / Octapharma
New P2 trial: Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease (clinicaltrials.gov) - Oct 24, 2017
P2, N=5, Not yet recruiting, Sponsor: Sutter Health
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial primary completion date, Surgery: FORMA-02: Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery (clinicaltrials.gov) - Oct 13, 2017
P3, N=24, Recruiting, Sponsor: Octapharma
Trial primary completion date: Mar 2019 --> Oct 2019
- ||||| Wilate (human factor VIII/von Willebrand factor) / Octapharma
Enrollment closed, Trial primary completion date: Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A (clinicaltrials.gov) - Oct 13, 2017
P3, N=55, Active, not recruiting, Sponsor: Octapharma
Trial primary completion date: Mar 2019 --> Oct 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Apr 2018
- Atenativ (human antithrombin III) / Octapharma
Trial withdrawal, Trial primary completion date: Atenativ Effect on Uterine Blood Flow and Preeclampsia (clinicaltrials.gov) - Sep 26, 2017
P4, N=0, Withdrawn, Sponsor: Vastra Gotaland Region
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Apr 2018 Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> May 2017
- || ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial initiation date, Trial primary completion date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Sep 21, 2017
P1b, N=150, Not yet recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> May 2017 Initiation date: Aug 2017 --> Mar 2018 | Trial primary completion date: Aug 2020 --> Apr 2021
- ||||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial initiation date: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (clinicaltrials.gov) - Sep 19, 2017
P3, N=140, Recruiting, Sponsor: Octapharma
Initiation date: Aug 2017 --> Mar 2018 | Trial primary completion date: Aug 2020 --> Apr 2021 Initiation date: Aug 2017 --> Nov 2017
- |||||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Enrollment open, Trial initiation date: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (clinicaltrials.gov) - Aug 4, 2017
P3, N=140, Recruiting, Sponsor: Octapharma
Initiation date: Aug 2017 --> Nov 2017 Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Aug 2017
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial withdrawal, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Jul 26, 2017
P2, N=0, Withdrawn, Sponsor: Astellas Institute for Regenerative Medicine
Not yet recruiting --> Recruiting | Initiation date: May 2017 --> Aug 2017 Terminated --> Withdrawn
- |||| Nuwiq (simoctocog alfa) / Octapharma
Trial primary completion date: Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - Jun 29, 2017
P3b, N=55, Recruiting, Sponsor: Octapharma
Terminated --> Withdrawn Trial primary completion date: Dec 2017 --> Sep 2018
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial primary completion date, Metastases: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) - Jun 14, 2017
P1/2, N=11, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Trial primary completion date: Dec 2017 --> Sep 2018 Trial primary completion date: Aug 2029 --> Dec 2019
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial primary completion date: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) - Jun 14, 2017
P1/2, N=13, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Trial primary completion date: Aug 2029 --> Dec 2019 Trial primary completion date: Aug 2029 --> Dec 2019
- ||| ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
New P1 trial: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Jun 5, 2017
P1b, N=150, Not yet recruiting, Sponsor: Astellas Institute for Regenerative Medicine
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment change, Trial termination, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Jun 5, 2017
P2, N=8, Terminated, Sponsor: Astellas Institute for Regenerative Medicine
Trial primary completion date: Aug 2029 --> Dec 2019 N=60 --> 8 | Suspended --> Terminated; Changes to the study design and the cell line
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
New P3 trial: Panzyga-CIDP: Panzyga in CIDP Administered at Different Infusion Rates (clinicaltrials.gov) - May 25, 2017
P3, N=30, Not yet recruiting, Sponsor: Vera Bril
- |||||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Enrollment open, Surgery: Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex (clinicaltrials.gov) - May 11, 2017
P3, N=370, Recruiting, Sponsor: Octapharma
N=60 --> 8 | Suspended --> Terminated; Changes to the study design and the cell line Not yet recruiting --> Recruiting
- || Trial initiation date: RESIST NAIVE: Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=148, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Initiation date: Jun 2009 --> Sep 2009
- Trial initiation date: RESIST EXP: Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=3, Active, not recruiting, Sponsor: City of Hope Medical Center
Initiation date: Jun 2009 --> Sep 2009 Initiation date: Jun 2009 --> Sep 2009
- || Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial primary completion date: Octagam 5% Versus Comparator Post Marketing Trial (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=500, Recruiting, Sponsor: Octapharma
Initiation date: Jun 2009 --> Sep 2009 Trial primary completion date: Mar 2017 --> Mar 2018
- |||||| Octagam (intravenous normal human immunoglobulin) / Octapharma
Enrollment open: ProDERM: Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) (clinicaltrials.gov) - Apr 10, 2017
P3, N=94, Recruiting, Sponsor: Octapharma
Trial primary completion date: Mar 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- |||||| Wilate (human factor VIII/von Willebrand factor) / Octapharma
Enrollment open: Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A (clinicaltrials.gov) - Mar 13, 2017
P3, N=55, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Wilate (human factor VIII/von Willebrand factor) / Octapharma
Enrollment closed, Trial primary completion date: Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Enrollment open, Head-to-Head, Surgery: FIBRES: FIBrinogen REplenishment in Surgery (clinicaltrials.gov) - Mar 1, 2017
P3, N=1200, Recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- ||||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial initiation date, Trial primary completion date: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (clinicaltrials.gov) - Feb 23, 2017
P3, N=140, Not yet recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Initiation date: Dec 2017 --> Mar 2017 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Gammanorm (human immune globulin subcutaneous) / Octapharma
Enrollment change, HEOR: A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push (clinicaltrials.gov) - Feb 8, 2017
P4, N=40, Recruiting, Sponsor: Octapharma
Initiation date: Dec 2017 --> Mar 2017 | Trial primary completion date: Dec 2018 --> Dec 2019 N=30 --> 40
- || Fibryga (fibrinogen concentrate (human)) / Octapharma
New P3 trial, Head-to-Head, Surgery: FIBRES: FIBrinogen REplenishment in Surgery (clinicaltrials.gov) - Jan 30, 2017
P3, N=1200, Not yet recruiting, Sponsor: University Health Network, Toronto
- | Privigen (human immune globulin intravenous 10%) / CSL Behring, Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion, Octagam (intravenous normal human immunoglobulin) / Octapharma
Enrollment open, Trial initiation date: Ig PRx in AECOPD: Pilot Study (clinicaltrials.gov) - Jan 24, 2017
P2, N=48, Recruiting, Sponsor: Ottawa Hospital Research Institute
N=30 --> 40 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Sep 2016
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial initiation date: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia (clinicaltrials.gov) - Nov 30, 2016
P3, N=40, Completed, Sponsor: Octapharma
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Sep 2016 Initiation date: Jun 2011 --> Oct 2011
- ||||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Trial initiation date, Surgery: Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex (clinicaltrials.gov) - Nov 23, 2016
P3, N=370, Not yet recruiting, Sponsor: Octapharma
Initiation date: Jun 2011 --> Oct 2011 Initiation date: Dec 2016 --> Mar 2017
- ||| Nuwiq (simoctocog alfa) / Octapharma
New trial: GENA-99: Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ (clinicaltrials.gov) - Nov 13, 2016
P=N/A, N=200, Recruiting, Sponsor: Octapharma
- |||||||||| Wilate (human factor VIII/von Willebrand factor) / Octapharma
New P3 trial: Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A (clinicaltrials.gov) - Nov 3, 2016
P3, N=55, Not yet recruiting, Sponsor: Octapharma
- || Nuwiq (simoctocog alfa) / Octapharma
Phase classification: Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - Oct 20, 2016
P3b, N=55, Recruiting, Sponsor: Octapharma
Initiation date: Dec 2016 --> Mar 2017 Phase classification: P3 --> P3b
- || Octagam (intravenous normal human immunoglobulin) / Octapharma
Enrollment change, Trial primary completion date: Octagam 5% Versus Comparator Post Marketing Trial (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=500, Recruiting, Sponsor: Octapharma
Phase classification: P3 --> P3b N=2500 --> 500 | Trial primary completion date: Dec 2019 --> Mar 2017
- ||| Octagam (intravenous normal human immunoglobulin) / Octapharma, Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial initiation date, Trial primary completion date: GAM 10-06: Non-Interventional Study on the Tolerability and Efficacy of IVIG (clinicaltrials.gov) - Oct 11, 2016
P4, N=1000, Not yet recruiting, Sponsor: Octapharma
N=2500 --> 500 | Trial primary completion date: Dec 2019 --> Mar 2017 Initiation date: Sep 2015 --> Mar 2017 | Trial primary completion date: Dec 2016 --> Dec 2017
- ||||| Nuwiq (simoctocog alfa) / Octapharma
Enrollment closed: NuProtect: Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients (clinicaltrials.gov) - Oct 6, 2016
P3, N=110, Active, not recruiting, Sponsor: Octapharma
Initiation date: Sep 2015 --> Mar 2017 | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- || Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial primary completion date: Octagam 5% Versus Comparator Post Marketing Trial (clinicaltrials.gov) - Aug 15, 2016
P=N/A, N=2500, Recruiting, Sponsor: Octapharma
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Dec 2019
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial primary completion date, HEOR: Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps (clinicaltrials.gov) - Aug 15, 2016
P4, N=30, Recruiting, Sponsor: Octapharma
Trial primary completion date: Aug 2016 --> Dec 2019 Trial primary completion date: Dec 2015 --> Dec 2017
- ||||| Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial initiation date: ProDERM: Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) (clinicaltrials.gov) - Aug 11, 2016
P3, N=94, Not yet recruiting, Sponsor: Octapharma
Trial primary completion date: Dec 2015 --> Dec 2017 Initiation date: Sep 2016 --> Dec 2016
- ||||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial initiation date: Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (clinicaltrials.gov) - Aug 8, 2016
P3, N=140, Not yet recruiting, Sponsor: Octapharma
Initiation date: Sep 2016 --> Dec 2016 Initiation date: Jun 2016 --> Dec 2017
- | Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial initiation date, Trial primary completion date, HEOR: A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push (clinicaltrials.gov) - Jul 19, 2016
P4, N=30, Recruiting, Sponsor: Octapharma
Initiation date: Jun 2016 --> Dec 2017 Initiation date: Nov 2014 --> Jul 2015 | Trial primary completion date: Dec 2016 --> Dec 2017
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment change, Trial withdrawal, Trial primary completion date: Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=0, Withdrawn, Sponsor: University of California, Los Angeles
Initiation date: Nov 2014 --> Jul 2015 | Trial primary completion date: Dec 2016 --> Dec 2017 N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2016
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial completion, Enrollment change: Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=12, Completed, Sponsor: Astellas Institute for Regenerative Medicine
N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2016 Active, not recruiting --> Completed | N=16 --> 12
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial completion, Trial primary completion date: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=13, Completed, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | N=16 --> 12 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial completion, Trial primary completion date, Metastases: Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=13, Completed, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Trial suspension, Surgery: PORTRAY: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (clinicaltrials.gov) - Jun 10, 2016
P2, N=60, Suspended, Sponsor: Astellas Institute for Regenerative Medicine
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Aug 2015 Recruiting --> Suspended
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment closed, Trial primary completion date, Metastases: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=11, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Recruiting --> Suspended Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029
- ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
Enrollment closed, Trial primary completion date: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) - Jun 10, 2016
P1/2, N=12, Active, not recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029